T1	Participants 126 159	Patients With Metabolic Syndrome.
T2	Participants 355 428	patients with metabolic syndrome, with and without stable statin therapy.
T3	Participants 472 819	evaluated patients with metabolic syndrome treated with IPE 4 grams/day, IPE 2 grams/day, or placebo in phase 3, randomized, placebo-controlled studies entitled: MARINE [triglyceride (TG) levels ≥500 and ≤2000 mg/dL] and ANCHOR [TG levels ≥200 and <500 mg/dL, despite low-density lipoprotein cholesterol (LDL-C) control with stable statin therapy]
